Jian Xu

Second Military Medical University, Shanghai, Shanghai, Shanghai Shi, China

Are you Jian Xu?

Claim your profile

Publications (4)7.58 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the expression of KIAA1199 in tumor tissue and its potential value as a prognostic indicator of survival in patients with colorectal cancer (CRC). The expression of KIAA1199 mRNA in CRC was characterized using real-time PCR and 20 pairs of fresh-frozen CRC tissues and corresponding non-cancerous tissues. KIAA1199 protein expression was confirmed using immunohistochemistry on a tissue microarray chip from 202 patients with CRC. Then, we correlated KIAA1199 protein expression to CRC conventional clinicopathological features and patient's outcome. The expression of KIAA1199 mRNA and protein were up-regulated in CRC compared to normal tissues (P = 0.015 and P < 0.001, individually). KIAA1199 protein expression was related to tumor invasion depth (P = 0.013) and lymph node metastasis (P = 0.003). Kaplan-Meier survival and Cox regression analyses revealed that high KIAA1199 expression (P < 0.001) and serum carcinoembryonic antigen (CEA) level post operation (P = 0.005) were independent factors predicting poor prognosis of patients with CRC. We present evidence that high expression of KIAA1199 is associated with tumor invasion depth, TNM stage, and poor prognosis in CRC. Our findings suggest KIAA1199 could be used as a prognostic factor and novel therapeutic target for CRC.
    No preview · Article · Jun 2015 · International journal of clinical and experimental pathology
  • Jian Xu · Liang Xu · Lintao Li · Siluo Zha · Zhiqian Hu
    [Show abstract] [Hide abstract]
    ABSTRACT: Transvaginal laparoscopic cholecystectomy (TVC) is becoming an attractive alternative to conventional laparoscopic cholecystectomy (CLC). We conducted a meta-analysis study to compare the outcome and side effects between TVC and CLC. Clinical studies on TVC with CLC as control were identified by searching PubMed and EMBASE (from 2007 to December 2013). Nine studies were identified for meta-analysis. Our results showed that TVC required much longer operative time [MD, 30.82; 95% confidence interval (CI), 13.00-48.65; P=0.0007] and had significantly lower pain score on postoperative day 1 as compared with CLC (MD, -1.77; 95% CI, -2.91 to -0.63; P=0.002). No statistical difference in days of hospital stay (MD, -1.60; 95% CI, -4.73 to 1.54; P=0.32) and number of complications was found between the 2 groups (risk ratio, 0.52; 95% CI, 0.25-1.10; P=0.09). Safety of TVC is similar as CLC. In conclusion, TVC patients have significantly less postoperative pain but need much longer operative time.
    No preview · Article · Jul 2014 · Surgical laparoscopy, endoscopy & percutaneous techniques
  • Jian Xu · Liang Xu · Lintao Li · Qing You · Luosi Cha
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Recent evidence suggests that genetic variations in the hypoxia inducible factor-1α (HIF-1α) gene may have an impact on an individual's susceptibility to gastrointestinal tract (GIT) cancer; but individually published results are inconclusive. This meta-analysis aims to derive a precise estimation of the association between a common polymorphism (C1772T; rs11549465 C>T) in the HIF-1α gene and susceptibility to GIT cancer. Methods: An extensive literature search was conducted for appropriate articles published before May 1st, 2013. This meta-analysis was performed using the STATA 12.0 software. The crude odds ratio with 95% confidence interval was calculated. Results: Six case-control studies were assessed with a total of 911 GIT cancer patients and 2774 healthy controls. Our meta-analysis indicated that the C variant of HIF-1α C1772T polymorphism appeared to confer an increased risk for GIT cancer. Further subgroup analyses indicated that the C variant of HIF-1α C1772T polymorphism may increase the risk of GIT cancer among Asian populations, but not among Caucasian populations. Univariate and multivariate meta-regression analyses confirmed that differences in ethnicity and cancer type are the major sources of heterogeneity. No publication bias was detected in this meta-analysis. Conclusion: The current meta-analysis suggests that the C variant of HIF-1α C1772T polymorphism may increase the risk of GIT cancer, especially among Asian populations.
    No preview · Article · Sep 2013 · Genetic Testing and Molecular Biomarkers
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Pancreatic cancer is one of the most lethal cancers worldwide. CD86 (B7-2) is a costimulatory molecule on antigen-presenting cells and plays critical roles in tumor immunity. It has been reported that polymorphisms in CD86 gene can be involved in the development of various cancers. Here, we investigated the association of two CD86 polymorphisms, +1057G/A (rs1129055) and +2379G/C (rs17281995), with pancreatic cancer in the Chinese population. Methods: The two polymorphisms were identified in 369 pancreatic cancer patients and 412 healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data were analyzed by chi-square test and adjusted for body mass index, smoking, drinking, and diabetes status. Results: Results showed that the frequency of the +1057A allele was significantly higher in pancreatic cancer cases than in controls (59.8 vs. 52.8 %, p = 0.021). Comparison of genotype frequencies showed that +1057GA and +1057AA genotypes were significantly increased in the pancreatic cancer group (odds ratio (OR) = 1.52; 95 % confidence interval (CI), 1.09-2.38; p = 0.026; and OR = 1.90; 95 % CI, 1.21-3.01; p = 0.007). We did not find any association between the +2379G/C polymorphism and pancreatic cancer. Analysis of haplotypes indicated that the AG (+1057, +2379) haplotype was correlated with the susceptibility to this disease (p = 0.019). Conclusions: These results suggest that the CD86 +1057G/A polymorphism and AG (+1057, +2379) haplotype are genetic risk factors for pancreatic cancer.
    No preview · Article · Jul 2012 · Journal of Cancer Research and Clinical Oncology